[DR3/LARD mRNA spliced variants' frequency at colorectal cancer]

Molekuliarnaia Biologiia
|December 17, 2014
PubMed

Insights

Alternative splicing creates death receptor DR3/LARD mRNA variants. Colon cancer patients exhibit reduced DR3/LARD mRNA diversity, particularly a decrease in soluble DR3beta mRNA, impacting apoptosis signaling.

Area of Science:

  • Molecular biology
  • Cancer research
  • Immunology

Context:

  • Alternative splicing of death receptor DR3/LARD mRNA generates diverse functional variants.
  • Membrane and soluble forms of DR3/LARD receptor play distinct roles in cellular processes.
  • Understanding DR3/LARD mRNA variant expression is crucial for cancer biology.

Purpose:

  • To investigate the frequency and diversity of DR3/LARD mRNA spliced variants in colon cancer.
  • To compare DR3/LARD mRNA expression patterns between healthy individuals and colon cancer patients.
  • To determine the association between DR3/LARD mRNA variant spectrums and colon cancer development.

Summary:

  • RT-PCR analysis revealed four DR3/LARD mRNA variants: two membrane-bound (LARD la, DR3beta) and two soluble (LARD 3, soluble DR3beta).
  • Healthy volunteers displayed 11 DR3/LARD mRNA spectrums, dominated by the "full" spectrum. Colon cancer patients and tumor tissues showed 6 spectrums.
  • A significant reduction in DR3/LARD mRNA diversity was observed in colon cancer patients, primarily due to decreased frequency of soluble DR3beta mRNA.

Impact:

  • The study identifies specific DR3/LARD mRNA spectrums associated with colon cancer, highlighting altered expression patterns.
  • Reduced diversity in DR3/LARD mRNA variants, particularly soluble DR3beta, may influence immune cell and tumor cell susceptibility to apoptosis.
  • Findings suggest potential diagnostic or prognostic biomarkers based on DR3/LARD mRNA expression profiles in colon cancer.